Annemans et al. [65]
|
50+
|
No vaccination
|
EUR 6,624/QALY; EUR 1,046/HZ case avoided; EUR 3,495-3,523/PHN case avoideda
|
EUR 6,822/QALY; EUR 1,077/HZ case avoided; EUR 3,600-3,629/PHN case avoideda
|
60+
|
No vaccination
|
EUR 6,809/QALY; EUR 1,310/HZ case avoided; EUR 3,942-3,969/PHN case avoideda
|
EUR 7,148/QALY; EUR 1,375/HZ case avoided; EUR 4,039-4,137/PHN case avoideda
|
65+
|
No vaccination
|
EUR 7,184/QALY; EUR 1,560/HZ case avoided; EUR 4,176-4,336/PHN case avoideda
|
EUR 7,577/QALY; EUR 1,645/HZ case avoided; EUR 4,404-4,574/PHN case avoideda
|
60-64
|
No vaccination
|
EUR 5,694/QALY; EUR 817/HZ case avoided; EUR 2,936-2,969/PHN case avoideda
|
EUR 5,867/QALY; EUR 842/HZ case avoided; EUR 3,025-3,059/PHN case avoideda
|
65-69
|
No vaccination
|
EUR 5,412/QALY; EUR 873/HZ case avoided; EUR 2,967-2,991/PHN case avoideda
|
EUR 5,628/QALY; EUR 909/HZ case avoided; EUR 3,087-3,112/PHN case avoideda
|
60-69
|
No vaccination
|
EUR 5,553/QALY; EUR 844/HZ case avoided; EUR 2,951-2,980/PHN case avoideda
|
EUR 5,747/QALY; EUR 874/HZ case avoided; EUR 3,054-3,085/PHN case avoideda
|
Bilcke et al. [38]
|
60
|
No vaccination
|
EUR 1,200-46,968/QALY; EUR 584–5,148/HZ case avoided
|
NA
|
70
|
No vaccination
|
EUR 2,200-70,496/QALY; EUR 1,239-8,603/HZ case avoided
|
NA
|
80
|
No vaccination
|
EUR 3,824-126,793/QALY; EUR 2,867-17,353/HZ case avoided
|
NA
|
85
|
No vaccination
|
EUR 5,272-291,240/QALY; EUR 4,451-42,164/HZ case avoided
|
NA
|
Bilcke et al. [30]
|
50 or 60
|
No vaccination
|
No results for a sole HZ vaccination reported; see Table 5 for results on combined varicella and HZ vaccination
|
NA
|
Bresse et al. [66]
|
65+
|
No vaccination
|
EUR 11,480/QALY; EUR 2,479/HZ case avoided; EUR 4,101/PHN case avoidedb
|
NA
|
70-79
|
No vaccination
|
EUR 8,876/QALY; EUR 2,090/HZ case avoided; EUR 3,302/PHN case avoidedb
|
NA
|
Brisson et al. [67]
|
50
|
No vaccination
|
EUR 36,667/QALY
|
NA
|
60
|
No vaccination
|
EUR 26,563/QALY
|
NA
|
65
|
No vaccination
|
EUR 24,002/QALY
|
NA
|
70
|
No vaccination
|
EUR 22,924/QALY
|
NA
|
80
|
No vaccination
|
EUR 33,153/QALY
|
NA
|
de Boer et al. [40]
|
60
|
No vaccination
|
EUR 40,050/QALY
|
EUR 33,901/QALY
|
65
|
No vaccination
|
EUR 34,440/QALY
|
EUR 33,511/QALY
|
70
|
No vaccination
|
EUR 28,491/QALY
|
EUR 28,284/QALY
|
75
|
No vaccination
|
EUR 28,506/QALY
|
EUR 28,506/QALY
|
Edmunds et al. [68]
|
65
|
No vaccination
|
EUR 5,435-100,700/QALYc
|
NA
|
Hornberger et al. [28]
|
69
|
No vaccination
|
NA
|
From cost-saving up to EUR 250,470/QALYd
|
Moore et al. [69]
|
50+
|
No vaccination
|
EUR 17,681/QALY; EUR 1,957/HZ case avoided; EUR 7,369-7,413/PHN case avoided
|
EUR 15,520/QALY; EUR 1,710/HZ case avoided; EUR 6,434-6,472/PHN case avoided
|
50-54
|
No vaccination
|
EUR 18,041/QALY
|
EUR 12,488/QALY
|
55-59
|
No vaccination
|
EUR 16,182/QALY
|
EUR 12,124/QALY
|
60-64
|
No vaccination
|
EUR 14,931/QALY
|
EUR 12,866/QALY
|
65-69
|
No vaccination
|
EUR 13,967/QALY
|
EUR 13,638/QALY
|
70-74
|
No vaccination
|
EUR 17,814/QALY
|
EUR 17,814/QALY
|
75-79
|
No vaccination
|
EUR 20,352/QALY
|
EUR 20,352/QALY
|
80-84
|
No vaccination
|
EUR 27,176/QALY
|
EUR 27,176/QALY
|
85-89
|
No vaccination
|
EUR 45,799/QALY
|
EUR 45,799/QALY
|
90-94
|
No vaccination
|
EUR 67,522/QALY
|
EUR 67,522/QALY
|
95-99
|
No vaccination
|
EUR 100,562/QALY
|
EUR 100,562/QALY
|
100+
|
No vaccination
|
EUR 140,125/QALY
|
EUR 140,125/QALY
|
Najafzadeh et al. [26]
|
60+
|
No vaccination
|
EUR 28,314/QALY
|
NA
|
60-74
|
No vaccination
|
EUR 24,002/QALY
|
NA
|
75+
|
No vaccination
|
EUR 44,123/QALY
|
NA
|
Pellissier et al. [70]
|
60+, general population
|
No vaccination
|
EUR 16,170/QALY
|
EUR 14,232/QALY
|
60+, immunocompetent only
|
No vaccination
|
EUR 24,211/QALY
|
EUR 22,255/QALY
|
Rothberg et al. [42]
|
60, male
|
No vaccination
|
NA
|
EUR 130,097/QALY
|
60, female
|
No vaccination
|
NA
|
EUR 81,076/QALY
|
70, male
|
No vaccination
|
NA
|
EUR 59,794/QALY
|
70, female
|
No vaccination
|
NA
|
EUR 39,512/QALY
|
80, male
|
No vaccination
|
NA
|
EUR 173,224/QALY
|
80, female
|
No vaccination
|
NA
|
EUR 111,779/QALY
|
Szucs et al. [71]
|
70-79
|
No vaccination
|
EUR 13,743/QALY; EUR 3,565/HZ case avoided; EUR 8,334/PHN case avoided
|
CHF 15,361/QALY; CHF 3,985/HZ case avoided; EUR 9,315/PHN case avoided
|
Ultsch et al. [39]
|
50
|
No vaccination
|
EUR 37,173/QALY; EUR 1,587/HZ case avoided; EUR 32,545/PHN case avoided
|
EUR 30,901/QALY; EUR 1,320/HZ case avoided; EUR 27,054/PHN case avoided
|
55
|
No vaccination
|
EUR 32,480/QALY; EUR 1,518/HZ case avoided; EUR 26,194/PHN case avoided
|
EUR 28,244/QALY; EUR 1,320/HZ case avoided; EUR 22,777/PHN case avoided
|
60
|
No vaccination
|
EUR 30,212/QALY; EUR 1,525/HZ case avoided; EUR 22,337/PHN case avoided
|
EUR 28,146/QALY; EUR 1,419/HZ case avoided; EUR 20,809/PHN case avoided
|
65
|
No vaccination
|
EUR 30,807/QALY; EUR 1,655/HZ case avoided; EUR 20,951/PHN case avoided
|
EUR 29,526/QALY; EUR 1,586/HZ case avoided; EUR 20,079/PHN case avoided
|
70
|
No vaccination
|
EUR 42,190/QALY; EUR 2,732/HZ case avoided; EUR 22,813/PHN case avoided
|
EUR 41,942/QALY; EUR 2,716/HZ case avoided; EUR 22,679/PHN case avoided
|
75
|
No vaccination
|
EUR 55,171/QALY; EUR 3,939/HZ case avoided; EUR 27,396/PHN case avoided
|
EUR 54,940/QALY; EUR 3,923/HZ case avoided; EUR 27,281/PHN case avoided
|
80
|
No vaccination
|
EUR 92,734/QALY; EUR 9,433/HZ case avoided; EUR 35,717/PHN case avoided
|
EUR 92,541/QALY; EUR 9,414/HZ case avoided; EUR 35,643/PHN case avoided
|
van Hoek et al. [72]
|
60
|
No vaccination
|
EUR 36,302/QALY
|
NA
|
65
|
No vaccination
|
EUR 27,747/QALY
|
NA
|
70
|
No vaccination
|
EUR 20,589/QALY
|
NA
|
75
|
No vaccination
|
EUR 25,211/QALY
|
NA
|
van Hoek et al. [33]
|
75
|
No vaccination
|
49 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY); 96 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)
|
NA
|
75 and 2-dose varicella vaccination of children
|
No vaccination
|
50 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY); 70 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)
|
NA
|
van Lier et al. [41]
|
60
|
No vaccination
|
EUR 39,577/QALY
|
EUR 37,638/QALY
|
65
|
No vaccination
|
EUR 30,514/QALY
|
EUR 30,514/QALY
|
70
|
No vaccination
|
EUR 21,219/QALY
|
EUR 21,219/QALY
|
75
|
No vaccination
|
EUR 23,779/QALY
|
EUR 23,779/QALY
|
80
|
No vaccination
|
EUR 33,661/QALY
|
EUR 33,661/QALY
|